ZA200400143B - Improved chelator conjugates. - Google Patents

Improved chelator conjugates.

Info

Publication number
ZA200400143B
ZA200400143B ZA200400143A ZA200400143A ZA200400143B ZA 200400143 B ZA200400143 B ZA 200400143B ZA 200400143 A ZA200400143 A ZA 200400143A ZA 200400143 A ZA200400143 A ZA 200400143A ZA 200400143 B ZA200400143 B ZA 200400143B
Authority
ZA
South Africa
Prior art keywords
chelator conjugates
improved
improved chelator
radiometal
conjugates
Prior art date
Application number
ZA200400143A
Other languages
English (en)
Inventor
Colin Mill Archer
Harry John Wadsworth
Torgrim Engell
Original Assignee
Amersham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amersham Plc filed Critical Amersham Plc
Publication of ZA200400143B publication Critical patent/ZA200400143B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C251/32—Oximes
    • C07C251/34—Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C07C251/36—Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with the carbon atoms of the oxyimino groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Optics & Photonics (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Medicinal Preparation (AREA)
ZA200400143A 2001-07-10 2004-01-08 Improved chelator conjugates. ZA200400143B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0116815.2A GB0116815D0 (en) 2001-07-10 2001-07-10 Improved chelator conjugates

Publications (1)

Publication Number Publication Date
ZA200400143B true ZA200400143B (en) 2004-12-29

Family

ID=9918227

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200400143A ZA200400143B (en) 2001-07-10 2004-01-08 Improved chelator conjugates.

Country Status (21)

Country Link
US (2) US7597875B2 (da)
EP (1) EP1404377B1 (da)
JP (1) JP5015409B2 (da)
KR (1) KR100892009B1 (da)
CN (4) CN101538313A (da)
AT (1) ATE304866T1 (da)
AU (1) AU2002317317B2 (da)
BR (1) BR0210965A (da)
CA (1) CA2450690C (da)
DE (1) DE60206272T2 (da)
DK (1) DK1404377T3 (da)
ES (1) ES2250671T3 (da)
GB (1) GB0116815D0 (da)
HK (1) HK1064585A1 (da)
HU (1) HU228850B1 (da)
IL (1) IL159388A0 (da)
MX (1) MXPA04000210A (da)
NO (1) NO334093B1 (da)
RU (1) RU2298012C2 (da)
WO (1) WO2003006070A2 (da)
ZA (1) ZA200400143B (da)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002054088A2 (en) * 2001-01-05 2002-07-11 Duke University Contrast enhancement agent for magnetic resonance imaging
HU230901B1 (hu) * 2001-07-10 2019-01-28 Ge Healthcare Limited Peptidalapú vegyületek és ezeket tartalmazó gyógyszerkészítmények
NO20030115D0 (no) * 2003-01-09 2003-01-09 Amersham Health As Kontrastmiddel
WO2005044313A2 (en) * 2003-11-06 2005-05-19 Amersham Health As Conjugates of angiotensin ii and an imaging moiety
GB0416062D0 (en) * 2004-07-19 2004-08-18 Amersham Plc Improved N4 chelator conjugates
EP1699494A2 (en) * 2003-11-24 2006-09-13 GE Healthcare AS Contrast agent imaging angiotensin ii receptors
WO2005084715A2 (en) * 2004-03-04 2005-09-15 Ge Healthcare As Conjugates of angiotensin peptidic analogues and chelating agents for diagnosis and therapy
AU2005307195A1 (en) * 2004-11-22 2006-05-26 Ge Healthcare As Contrast agents to target extracellular matrix
WO2006131803A2 (en) * 2005-06-08 2006-12-14 Ge Healthcare Limited Method for the use of [11c] carbon monoxide in labeling synthesis of 11c-labelled esters and acids by sensitized photo-induced free radical carbonylation
GB0515974D0 (en) * 2005-08-03 2005-09-07 Ge Healthcare Ltd Compounds and imaging methods
CN101379023A (zh) 2006-02-15 2009-03-04 通用电气医疗集团股份有限公司 造影剂
US7943117B2 (en) * 2006-06-08 2011-05-17 Atomic Energy Council—Institute of Nuclear Research Method for testing radiochemical purity of Tc-99m-TRODAT-1
RU2009119917A (ru) * 2006-12-11 2011-01-20 ДжиИ Хелткер АС (NO) Соединения на основе меченных радиоактивным изотопом пептидов и их применения
ES2712881T3 (es) 2008-12-02 2019-05-16 Univ Melbourne Conjugados macrocíclicos que contienen nitrógeno como radiofármacos
GB0922014D0 (en) 2009-12-17 2010-02-03 Ge Healthcare Ltd Novel integrin binders
CN103108659A (zh) * 2010-07-27 2013-05-15 通用电气健康护理有限公司 放射性药物组合物
GB201103696D0 (en) * 2011-03-04 2011-04-20 Ge Healthcare Ltd Technetium labelled peptides
GB201110767D0 (en) 2011-06-24 2011-08-10 Ge Healthcare Ltd Infection imaging
US20130195756A1 (en) 2012-01-31 2013-08-01 General Electric Company 99mTc IMAGING AGENTS AND METHODS OF USE
US20150374861A1 (en) * 2013-02-15 2015-12-31 Thomas Jefferson Unversity Kit for tumor imaging
GB201314936D0 (en) 2013-08-21 2013-10-02 Ge Healthcare Ltd Radiolabelling method
GB201322456D0 (en) 2013-12-18 2014-02-05 Ge Healthcare Ltd Radiotracer compositions and methods
PT3131585T (pt) 2014-03-19 2020-10-23 Univ Zuerich Agentes quelantes bifuncionais multidentados para complexação de radionuclídeos em diagnóstico e terapia
EP3790975A4 (en) * 2018-05-08 2022-10-26 University of Miami MATERIALS AND METHODS FOR DELIVERING THERAPEUTIC NUCLEIC ACIDS TO TISSUE
CN112105393A (zh) 2018-05-16 2020-12-18 爱默蕾大学 苯乙烯基苯并噻唑衍生物及在成像中的用途
CN111548275A (zh) * 2020-05-27 2020-08-18 龙曦宁（上海）医药科技有限公司 一种2-（氨基甲基）-n1,n1-二甲基丙烷-1,3-二胺三盐酸盐的合成方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1588978A (en) * 1977-07-19 1981-05-07 Ici Ltd Coating processes
DE3930674A1 (de) * 1989-09-11 1991-03-21 Diagnostikforschung Inst Bifunktionelle chelatbildner zur komplexierung von tc- und re-isotopen, verfahren zu ihrer herstellung und darstellung von konjugaten daraus sowie deren verwendung in diagnostik und therapie
US5808091A (en) * 1991-10-29 1998-09-15 Bracco International B.V. Rhenium and technetium complexes containing a hypoxia localizing moiety
CA2168652A1 (en) * 1993-08-04 1995-02-16 Colin Mill Archer Radiometal complexes that localise in hypoxic tissue
DE69526203T2 (de) * 1994-01-12 2002-11-28 Amersham Plc, Little Chalfont Biologische zielgerichtete mittel
EP0688313B1 (en) * 1994-01-12 1998-04-08 BRACCO International B.V. Ligands and metal complexes thereof
EP1077998B1 (en) 1998-05-15 2008-01-16 GE Healthcare Limited Labelled glutamine and lysine analogues
US6783711B2 (en) * 2000-05-23 2004-08-31 Ge Osmonics, Inc. Process for preparing a sulfonamide polymer matrix
JP4009198B2 (ja) 2001-03-08 2007-11-14 松下電器産業株式会社 インクジェット記録用インク、該インクの製造方法、並びに該インクを備えたインクカートリッジ及び記録装置

Also Published As

Publication number Publication date
AU2002317317B2 (en) 2005-11-17
WO2003006070A2 (en) 2003-01-23
HU228850B1 (en) 2013-06-28
CN100509061C (zh) 2009-07-08
DE60206272T2 (de) 2006-07-13
IL159388A0 (en) 2004-06-01
US20040258619A1 (en) 2004-12-23
KR20040017287A (ko) 2004-02-26
NO334093B1 (no) 2013-12-09
CN101607913A (zh) 2009-12-23
ES2250671T3 (es) 2006-04-16
NO20035597D0 (no) 2003-12-16
HUP0401265A2 (hu) 2004-09-28
BR0210965A (pt) 2004-06-08
ATE304866T1 (de) 2005-10-15
NO20035597L (no) 2004-03-03
DE60206272D1 (de) 2005-10-27
EP1404377A2 (en) 2004-04-07
CA2450690C (en) 2009-03-24
RU2298012C2 (ru) 2007-04-27
CN101537190A (zh) 2009-09-23
CN1527727A (zh) 2004-09-08
DK1404377T3 (da) 2006-01-30
JP5015409B2 (ja) 2012-08-29
EP1404377B1 (en) 2005-09-21
US7597875B2 (en) 2009-10-06
KR100892009B1 (ko) 2009-04-07
HUP0401265A3 (en) 2005-11-28
CN101607913B (zh) 2012-07-04
US20100040542A1 (en) 2010-02-18
WO2003006070A3 (en) 2003-08-21
US8852550B2 (en) 2014-10-07
GB0116815D0 (en) 2001-08-29
CA2450690A1 (en) 2003-01-23
RU2003137592A (ru) 2005-05-20
CN101538313A (zh) 2009-09-23
MXPA04000210A (es) 2004-07-23
HK1064585A1 (en) 2005-02-04
JP2005500325A (ja) 2005-01-06

Similar Documents

Publication Publication Date Title
GB0116815D0 (en) Improved chelator conjugates
MXPA05009682A (es) Metodos de radiofluorinacion de vectores biologicamente activos.
PL1791571T3 (pl) Radiofluorowane peptydy
YU27403A (sh) Postupak za pripremanje preparata u obliku praha
MXPA03006093A (es) Derivados de n(fenilsulfonil)glicina y su uso terapeutico.
HK1068626A1 (en) Chemical compounds
MY140739A (en) 2, 6-quinolinyl derivatives, processes for preparing them and their uses
TWI268278B (en) 2,6-quinolinyl and 2,6-naphthyl derivatives, processes for preparing them and their uses
WO2003104425A3 (en) NEW STABLE ANTI-CD22 ANTIBODIES
SI1831239T1 (sl) Postopek za pripravo gamma laktona hidroksi beta beta beta beta bismetilen alfa pregn en on karboksilne kisline in ključniintermediati za ta postopek
DE60210598D1 (de) 3,7-DIAZABICYCLOc3.3.1Ü-FORMULIERUNGEN ALS ANTIARRHYTHMIKA
GB0105224D0 (en) Improved peptide-chelate conjugates
TW200732345A (en) Niobium compound
DE60322562D1 (de) Konjugate von tc komplexen und zielgerichtete einheiten und ihre verwendung in nmr-diagnostik
PL352104A1 (en) Oral composition containing perlite
DE60213084D1 (de) 3,7-DIAZABICYCLOc3.3.1Ü-FORMULIERUNGEN ALS ANTIARRHYTHMIKA
ID27733A (id) Metoksiminofenilasetamida
MXPA05008108A (es) Exo-(2r)(+))-2-amino-7-azabiciclo[2.2.1]heptan-7-carboxilato de terc-butilo, compuestos intermedios y procedimiento para prepararlos y aislarlos.
NO20021429L (no) 1,4-dioksacykloalkan-2-oner og 1,4-dioksacykloalken-2-oner
ITMI20030827A1 (it) Composizione farmaceutica contenente l'associazione levodopa/carbidopa.
TW200407314A (en) Preparation of 4, 6-dichloro-5-fluoropyrimidine
UA86379C2 (ru) Азотосодержащие гетероарильные соединения и их применение при повышении эндогенного эритропоэтина
BG103595A (en) Metoprolol compound and methods for its preparation
TW200519206A (en) Methods for producing novel medaka and novel medaka